come well-below heighten
expect ramp focu
broad miss flat cc sale growth ep
sale well-below street bofaml est
flat constant currenc cc growth vs guid our/street expect
fx top-lin miss flow margin lower volum lead
adj ep vs street first look overview result
went wrong number thing
rebound saw improv sever key indic blame
shortfal key issu declin china organ sale tie government restructur
food safeti ministri low capit purchas gener manufactur europ
soft cc sale growth brexit macro condit weak capit spend
industrial/pharma account declin thermal analysi ta segment
even beyond troubl area part busi also uninspir ie
flat pharma sale growth overal us sale growth/flat america growth
outlook reduc confid visibl
lower prior guid cc sale growth vs prior lower
adj ep vs prior notabl compani expect
gradual stabil progress year cc sale growth
prior expect despit view much shortfal
resolv end-market gradual improv addit management continu
emphas steadi progress product launch bioaccord lc/m
promin contribut improv perform improv end-
market new product introduct could point upsid conserv
estim see miss indic reduc visibl substanti
quarterli miss past quarter take cautiou view recoveri
tweak estim reiter neutral lower po
lower sale estim well adj
ep estim see subdu recoveri cours
year model organ growth reiter neutral rate
lower po estimate prior due cautiou outlook
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
corp lead supplier
analyt instrument consum
product use mainli research
qualiti assur applic pharmaceut
life scienc biochem industri academ
govern custom compani
posit liquid chromatographi market
busi posit
mass spectrometri market
posit thermal analysi market
water face difficult market condit
product cycl share shift market
expect continu soft perform
near-term believ dynam take
time play expect compani
benefit share buyback low expect
po base ep estim in-lin
compani lst peer group modest premium compani averag two year
histor multipl past five year due potenti new product cycl
back dcf analysi assum wacc termin growth rate
slow china tariff/trad war escal slower expect capit
deploy weaker global economi share loss competitor failur new
product deliv slowdown pharma biotech spend downsid risk
price object
upsid risk po faster expect capit deploy faster
expect uptak new product acquisit compani
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us life scienc diagnost tool anim health coverag cluster
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
